This post was originally published on Medscape
You will shortly be re-directed to the publisher's website
Sotagliflozin, a dual SGLT1/2 inhibitor, reduces cardiovascular events in people with diabetic kidney disease — ischemic benefits not observed in trials of selective SGLT2 inhibitors.
Medscape Medical News